While microarray technology is broadening its applications in genomics and proteomics, the technique remains a vibrant contributor in the area of gene expression. Much of the overall developmental ...

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that research demonstrating the ...

Tissue microarray (TMA) technology has transformed colorectal cancer research by enabling simultaneous analysis of hundreds of tissue samples under uniform experimental conditions. In this approach, ...

Scientists at the Leibniz Institute of Photonic Technology (Leibniz IPHT) have developed a new microarray-based diagnostic platform that can help close vaccination gaps and quickly detect ...

The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...

Vaxxas holds an exclusive license from The University of Texas at Austin (UTA) to the SARS-CoV-2 spike subunit vaccine (HexaPro) for vaccination using a patch. HexaPro, a second-generation SARS-CoV-2 ...

The human genome project was undertaken to determine the human DNA sequence and analyze variation among individuals. To make use of this information, tools were developed that could collect and ...

KRAS mutation in the primary or acquired resistance of Chinese NSCLC to EGFR tyrosine kinase inhibitors No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the ...

The mutation status of the epidermal growth factor receptor (EGFR) as a selection criterion for therapy with EGFR tyrosine kinase inhibitors (TKI’s) in non-small cell lung cancer (NSCLC) No ...

Launched in 1990, The Human Genome Project was a monumental effort to sequence and analyze the entire human genome to understand how genetics influence health. While the Human Genome Project helped ...